miR-28 plus ibrutinib as a novel combination therapy for Diffuse Large B Cell Lymphoma
T. Fuertes, E. Alvarez-Corrales, P. Ubieto-Capella, A. Serrano-Navarro, C. Gomez-Escolar, A. de Molina, J. Mendez, A. R. Ramiro, V. G. de Yebenes
This paper investigates the combination of miR-28 and ibrutinib as a therapy for DLBCL, showing enhanced anti-tumor effects and a new gene signature for prognosis.
bioRxiv · Sep 27, 2022Cancer Biology